Esperion Therapeutics, Inc.
About Esperion Therapeutics, Inc.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $403.1M
- Net income
- -$22.7M
- Total assets
- $465.9M
- Market cap
- $805.8M
- Operating margin
- 15.0%
- Net margin
- -5.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $403.1M
- Operating expenses
- $342.9M
- Operating income
- $60.3M
- Income tax
- $1.8M
- Net income
- -$22.7M
- EPS (basic)
- $-0.11
- EPS (diluted)
- $-0.11
Balance sheet
- Total assets
- $465.9M
- Current assets
- $462.6M
- Total liabilities
- $767.9M
- Current liabilities
- $300.8M
- Shareholders’ equity
- -$302.0M
Cash flow
- Operating cash flow
- -$13.1M
- Investing cash flow
- -$23.1M
- Financing cash flow
- $36.2M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $805.8M
- EPS (diluted)
- $-0.11
- Shares outstanding
- 255.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 26, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $22.7M in FY2025.
- Revenue grew 414% from FY2021 to FY2025.
- Trading 23% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Esperion Therapeutics, Inc..
Write a review
News about Esperion Therapeutics, Inc.
News & sentiment via Polygon.io
